Our Story

A Leading Biotechnology Company 

Since forming in 2010, BCAL Diagnostics has been focussing on detection of women’s health issues.

​

Published studies shows that there is an association between breast cancer and some specific lipids. This change is detectable directly in breast cancer tissue and cells. The role of these lipids in disease is still being fully understood but their value as metabolites of interest has been established.
 
In parallel, but entirely independently, researchers in the US, had carried out a similar study and found that some the same lipids were changing significantly between those with the disease compared to controls.

​

​BCAL Diagnostics, in collaboration with the US researchers completed a study reaffirming the results of previous studies carried out by both groups with preliminary indications of around 90% accuracy.

​

In late 2017, BCAL Diagnostics brought the science back to Australia and is now based at the Charles Perkins Centre in Sydney University and Sydney Knowledge Hub. Since 2018, BCAL analysed around 490 freshly collected Invasive Ductal Carcinoma (IDC) and matched control samples in 3 cohorts. We have focused on IDC as it forms 70-80% of all diagnosed invasive breast cancer cases, while collecting high quality fresh samples to include other breast cancer types.  We have identified a panel of markers that can distinguish healthy from IDC at early Stages (Stage I & II), with sensitivity as high as 90%.

​

BCAL Diagnostics is developing a novel blood screening tool that provide additional information for clinicians to use alongside standard screening, monitoring and detection methods. 

​